Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 20, 2007 Ryan Fuhrmann	Discerning Pfizer's Pfuture The company is undergoing a transformation, but that doesn't mean it isn't worth a look from investors.
The Motley Fool January 24, 2008 Brian Lawler	Pfiltering Through Pfizer's Year Pfizer releases its 2007 numbers, displaying year-over-year earnings growth powered by foreign currency gains.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
The Motley Fool February 28, 2011 Brian Orelli	Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out?
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull Rebuttal The patent expirations are an issue, but the cash is what's really important. Investors, take note.
The Motley Fool January 23, 2007 Ryan Fuhrmann	Pfizer Pfizzles Through 2006 The company is in a top-line pickle, but it expects things to get better. Current investors are now left standing until a rebound in growth, now targeted for 2009.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008.
The Motley Fool December 13, 2011 Brian Orelli	Dividend? Buyback? Here's How to Get Both. But will there be enough to replenish the pipeline?
The Motley Fool January 14, 2008 Brian Lawler	Worst Stock for 2008: Pfizer This analyst thinks that Pfizer is a good company, but a bad stock for 2008.
The Motley Fool April 29, 2011 Brian Orelli	Show Us the Money, Drugmakers Drugmakers have cash and they aren't afraid to use it -- on themselves.
The Motley Fool April 21, 2008 Brian Lawler	Pfizer Is Still Floundering Generic competition keeps pounding away at its sales and profits.
The Motley Fool January 23, 2007 Ryan Fuhrmann	Back to the Future at Pfizer Pfizer just provided guidance for the next couple of years. The news shows that the company is willing to shake things up, but investors should remain skeptical until tangible benefits occur.
The Motley Fool October 22, 2007 Brian Lawler	Not Another Pfizer Pfailure As Pfizer's top execs have said before, losing patent protections on many of its top products around the same time makes for a difficult operating environment. Pfizer's third-quarter results showed just how difficult those losses were.
The Motley Fool June 8, 2011 Brian Orelli	Blockbuster Drug-Like Profits, No FDA Required Pfizer keeps the cuts coming.
The Motley Fool July 18, 2007 Ryan Fuhrmann	Pfizer Prepares for L-Day Will Pfizer be able to offset the looming loss of Lipitor? Investors, take note.
The Motley Fool October 20, 2006 Brian Lawler	Pfizer Keeps Fighting If Pfizer's management can succeed on its cost-savings initiatives and maintain the high single digits of earnings-per-share growth that it expects in 2007-2008, then Pfizer may make a good investment for those willing to wait for the company's new drugs to bring back higher growth.
The Motley Fool January 26, 2009 Brian Orelli	Deja Vu All Over Again There's hardly anything to like about Pfizer's deal to buy Wyeth. This is what got Pfizer into its problem in the first place.
The Motley Fool December 18, 2008 Brian Orelli	Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.
The Motley Fool January 19, 2007 Ryan Fuhrmann	The Best Drug Stock for 2007: Pfizer Investors, this is a great company at a great price.
The Motley Fool February 3, 2010 Brian Orelli	Wyeth Can't Save Pfizer Not much earnings growth, but the price is right.
The Motley Fool September 11, 2007 Brian Lawler	Looking Forward at Pfizer With generic competition on the way for Pfizer's top drug, Lipitor, the company stepped up to the podium at the Bear Stearns Healthcare Conference this week to let investors know its plans.
Chemistry World April 6, 2011 Andrew Turley	Pfizer sells capsule business for $2.4bn Investment firm Kohlberg Kravis Roberts has agreed to pay $2.4 billion in cash for the business, which it says has 'an excellent portfolio'.
The Motley Fool November 1, 2004 Selena Maranjian	Big Buybacks Some big companies are planning big buybacks, benefiting investors. IBM... Pfizer... etc.
The Motley Fool October 30, 2009 Brian Orelli	World's Scariest Stocks: Pfizer For Pfizer, the big, scary unknown comes from whether it can integrate its recent acquisition of Wyeth.
The Motley Fool December 14, 2005 Steven Mallas	Pfizer: Of Drugs and Dividends Pfizer is raising its payout. Is it a good move for the drugmaker? Investors willing to hold for years while reinvesting dividends will most likely be rewarded along the way.
The Motley Fool June 11, 2008 Brian Lawler	Dueling Fools: Pfizer Bear Is Pfizer ready for a comeback? The bearish opinion is that shares may be down, but the bleeding still isn't over.
The Motley Fool November 30, 2011 Brian Orelli	3 Things More Important to Pfizer Than Losing Lipitor It's not like we didn't see it coming.
The Motley Fool April 25, 2011 Brian Orelli	Dividend Investors Rejoice! Or Not. Amgen establishes a dividend, investors yawn.
The Motley Fool July 20, 2006 Stephen D. Simpson	Pfizer's Big Plans Between the launch of inhaled insulin and spending $34 billion, Pfizer has a lot on its plate. Investors, take note.
The Motley Fool December 4, 2006 Michael Leibert	Whither Pfizer? Bad news follows the upbeat message delivered at Pfizer's R&D briefing. But with strong cash flows, a healthy dividend yield, unparalleled scale, and a discounted share price, Pfizer's risk/reward profile might look attractive to investors.
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
Chemistry World April 29, 2014 Phillip Broadwith	Pfizer courts AstraZeneca megamerger US-based pharma behemoth Pfizer has publically announced its intention to make a merger offer to the UK's AstraZeneca, in a deal valued at around $100 billion.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear Rebuttal Generic competition for Lipitor is just the beginning. Faith is nice in terms of religion, but when it comes to investments, investors need to be able to make some reasonable assumptions about future growth plans.
The Motley Fool April 28, 2009 Brian Orelli	The Costs of Being Pfizer With Pfizer having announced its intention to buy Wyeth this quarter, investors may have worried that the negotiating and pre-acquisition planning caused management to be distracted, but that doesn't seem to be the case.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Mixed Foliage at Forest Labs Here's what to look for as Forest Labs prepares for a big loss. Investors, take note.
The Motley Fool May 4, 2010 Brian Orelli	Earnings Growth Trumps Revenue Growth, Except Here A solid quarter for Pfizer, but is there more in the tank?
The Motley Fool July 29, 2011 Brian Orelli	Merck's Making All the Right Long-Term Moves Job cuts, but they're not in research.
The Motley Fool July 24, 2008 Brian Lawler	Will Pfizer Pfizzle? The drugmaker posts strong earnings, but the good times may not last.
The Motley Fool February 29, 2008 Brian Orelli	2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed.
The Motley Fool January 28, 2010 Brian Orelli	Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds.
The Motley Fool December 7, 2010 Brian Orelli	How Pfizer's New Chief Can Right the Ship Bigger is not always better.
The Motley Fool January 30, 2007 Brian Lawler	Pfizer Fights a Generic Threat Pfizer attempts to fend off a generic threat in Canada for its top drug. It's a trial worth paying attention to for its shareholders, as Canada does represent one of the larger pharmaceutical markets in the world.
The Motley Fool June 19, 2008 Brian Lawler	Pfizer's Small Lipitor Win Pfizer and the most prolific challenger of its Lipitor patents, Indian generic-drug manufacturer Ranbaxy, settle the vast majority of their litigation.
The Motley Fool March 26, 2009 Brian Orelli	Big Pharma's R&D Model Is Broken Bigger isn't always better.
The Motley Fool June 1, 2007 Brian Lawler	The Generic Cracks Open for Pfizer Pfizer loses a patent case over its top compound. The larger takeaway from the Lipitor legal saga is that investors always need to be aware of the strength of a drug company's patents throughout the world.
The Motley Fool March 3, 2009 Brian Orelli	Pfizer Eyes Generic Growth Two partnerships in one day? Oh my!
The Motley Fool October 1, 2008 Brian Orelli	Is Pfizer the Mystery Bidder? A few signals that Pfizer might be the one bidding on ImClone.
The Motley Fool December 19, 2005 Stephen D. Simpson	Pfizer Wins, a Sector Rejoices The pharmaceutical dodges a bullet and investors find renewed enthusiasm for big-cap pharma.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.